520 related articles for article (PubMed ID: 25974382)
1. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.
Cibeira MT; Oriol A; Lahuerta JJ; Mateos MV; de la Rubia J; Hernández MT; Granell M; Fernández de Larrea C; San Miguel JF; Bladé J;
Br J Haematol; 2015 Sep; 170(6):804-13. PubMed ID: 25974382
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.
Palladini G; Russo P; Milani P; Foli A; Lavatelli F; Nuvolone M; Perlini S; Merlini G
Haematologica; 2013 Mar; 98(3):433-6. PubMed ID: 22983583
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.
Kumar SK; Hayman SR; Buadi FK; Roy V; Lacy MQ; Gertz MA; Allred J; Laumann KM; Bergsagel LP; Dingli D; Mikhael JR; Reeder CB; Stewart AK; Zeldenrust SR; Greipp PR; Lust JA; Fonseca R; Russell SJ; Rajkumar SV; Dispenzieri A
Blood; 2012 May; 119(21):4860-7. PubMed ID: 22504925
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
Mahmood S; Venner CP; Sachchithanantham S; Lane T; Rannigan L; Foard D; Pinney JH; Gibbs SD; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Br J Haematol; 2014 Sep; 166(6):842-8. PubMed ID: 24930361
[TBL] [Abstract][Full Text] [Related]
5. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
[TBL] [Abstract][Full Text] [Related]
6. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial.
Sanchorawala V; Patel JM; Sloan JM; Shelton AC; Zeldis JB; Seldin DC
Haematologica; 2013 May; 98(5):789-92. PubMed ID: 23144200
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis.
Chari A; Barley K; Jagannath S; Osman K
Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):55-61. PubMed ID: 23098888
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
Kastritis E; Roussou M; Gavriatopoulou M; Migkou M; Kalapanida D; Pamboucas C; Kaldara E; Ntalianis A; Psimenou E; Toumanidis ST; Tasidou A; Terpos E; Dimopoulos MA
Am J Hematol; 2015 Apr; 90(4):E60-5. PubMed ID: 25580702
[TBL] [Abstract][Full Text] [Related]
9. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
[TBL] [Abstract][Full Text] [Related]
10. Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.
Hazenberg BP; Croockewit A; van der Holt B; Zweegman S; Bos GM; Delforge M; Raymakers RA; Sonneveld P; Vellenga E; Wijermans PW; von dem Borne PA; van Oers MH; de Weerdt O; Spoelstra FM; Lokhorst HM;
Haematologica; 2015 May; 100(5):677-82. PubMed ID: 25661441
[TBL] [Abstract][Full Text] [Related]
11. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
12. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis.
Kastritis E; Terpos E; Roussou M; Gavriatopoulou M; Pamboukas C; Boletis I; Marinaki S; Apostolou T; Nikitas N; Gkortzolidis G; Michalis E; Delimpasi S; Dimopoulos MA
Blood; 2012 Jun; 119(23):5384-90. PubMed ID: 22517904
[TBL] [Abstract][Full Text] [Related]
13. [Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].
Adam Z; Stork M; Pour L; Krejčí M; Zahradová L; Sandecká V; Hájek R; Cermáková Z; Pospíšilová Y; Navrátil M; Král Z; Mayer J
Vnitr Lek; 2012 Dec; 58(12):896-903. PubMed ID: 23427947
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.
Dinner S; Witteles W; Afghahi A; Witteles R; Arai S; Lafayette R; Schrier SL; Liedtke M
Haematologica; 2013 Oct; 98(10):1593-9. PubMed ID: 23716538
[TBL] [Abstract][Full Text] [Related]
15. A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis.
Venner CP; Gillmore JD; Sachchithanantham S; Mahmood S; Lane T; Foard D; Rannigan L; Gibbs SD; Pinney JH; Whelan CJ; Lachmann HJ; Hawkins PN; Wechalekar AD
Leukemia; 2014 Dec; 28(12):2304-10. PubMed ID: 25027514
[TBL] [Abstract][Full Text] [Related]
16. Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant.
Warsame R; Bang SM; Kumar SK; Gertz MA; Lacy MQ; Buadi F; Dingli D; Hayman SR; Kapoor P; Kyle RA; Leung N; Lust JA; Russell SJ; Witzig TE; Zeldenrust SR; Rajkumar SV; Dispenzieri A
Eur J Haematol; 2014 Jun; 92(6):485-90. PubMed ID: 24502602
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.
Hegenbart U; Bochtler T; Benner A; Becker N; Kimmich C; Kristen AV; Beimler J; Hund E; Zorn M; Freiberger A; Gawlik M; Goldschmidt H; Hose D; Jauch A; Ho AD; Schönland SO
Haematologica; 2017 Aug; 102(8):1424-1431. PubMed ID: 28522573
[TBL] [Abstract][Full Text] [Related]
18. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.
Dispenzieri A; Lacy MQ; Zeldenrust SR; Hayman SR; Kumar SK; Geyer SM; Lust JA; Allred JB; Witzig TE; Rajkumar SV; Greipp PR; Russell SJ; Kabat B; Gertz MA
Blood; 2007 Jan; 109(2):465-70. PubMed ID: 17008538
[TBL] [Abstract][Full Text] [Related]
19. [Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
Charliński G; Wiater E; Jedrzejczak WW
Pol Merkur Lekarski; 2012 Apr; 32(190):217-20. PubMed ID: 22708276
[TBL] [Abstract][Full Text] [Related]
20. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
